Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBAMYCIN vs COMBUNOX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
COMBUNOX is a fixed-dose combination of oxycodone, a full mu-opioid receptor agonist, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.
FDA-approved for treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) when other agents are not suitable,Off-label: used for severe staphylococcal and enterococcal infections
FDA-approved: Short-term (up to 7 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.,Off-label: None commonly recognized.
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
1 tablet (ibuprofen 400 mg/oxycodone HCl 10 mg) orally every 4 to 6 hours as needed for pain; maximum 4 tablets per day.
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
Oxycodone terminal half-life is 3.5-5.5 hours (mean ~3.8 hours) in immediate-release form; controlled-release formulations have a prolonged absorption phase with an effective half-life of 4.5-8 hours. Ibuprofen terminal half-life is 1.8-2.5 hours (mean ~2 hours). Clinical context: Oxycodone's half-life supports dosing every 4-6 hours (IR) or 12 hours (CR); ibuprofen's short half-life requires frequent dosing for sustained anti-inflammatory effect. In elderly or hepatic impairment, oxycodone half-life may increase to 6-8 hours; ibuprofen half-life may be slightly prolonged.
Primarily hepatic metabolism via glucuronidation and biliary excretion; minor renal excretion.
Oxycodone: Primarily hepatic via CYP3A4 and CYP2D6 to active and inactive metabolites. Ibuprofen: Hepatic via CYP2C9 to inactive metabolites; also undergoes glucuronidation.
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
Oxycodone is primarily metabolized in the liver; metabolites are excreted mainly in urine. Approximately 87% of an oral dose is eliminated within 24 hours: 60-70% as oxycodone metabolites (mostly noroxycodone and oxymorphone conjugates) and 10-15% as unchanged oxycodone. Ibuprofen is rapidly metabolized and excreted; about 90% of a dose is eliminated in urine as metabolites (primarily hydroxylated and carboxylated forms) and <1% as unchanged drug. Biliary/fecal elimination accounts for <10% of each component.
25-30%, primarily to albumin.
Oxycodone: ~45% bound primarily to albumin. Ibuprofen: >99% bound to albumin. No displacement interactions likely at therapeutic concentrations.
0.25-0.35 L/kg, indicating distribution primarily into extracellular fluid.
Oxycodone: Vd of 2.0-3.0 L/kg (mean ~2.6 L/kg), indicating extensive tissue distribution. Ibuprofen: Vd of 0.1-0.2 L/kg (mean ~0.15 L/kg), confined to plasma and extracellular fluid. Combined formulation Vd not significantly altered.
Oral: 30-40% (variable due to first-pass metabolism); IM: 80-90%; IV: 100%.
Oral bioavailability of oxycodone: 60-87% (mean ~75%) with first-pass metabolism accounting for ~25% loss. Ibuprofen: >80% (mean ~95%) with minimal first-pass effect. Food reduces rate but not extent of absorption; taking with food may delay peak concentrations by 1-2 hours.
GFR 30-89 m L/min: Administer 5-10 mg/kg IV every 12 hours. GFR 15-29 m L/min: Administer 5-10 mg/kg IV every 24 hours. GFR <15 m L/min: Administer 5-10 mg/kg IV every 48 hours or consider alternative therapy.
GFR 30-89 m L/min: No adjustment needed. GFR <30 m L/min: Avoid use due to ibuprofen component. Hemodialysis: Not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25%. Child-Pugh Class C: Use with caution; consider 50% dose reduction.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce oxycodone dose by 50% (e.g., consider alternative). Child-Pugh C: Avoid use (contraindicated).
Infants and children: 10 mg/kg IV every 8 hours. Maximum daily dose: 30 mg/kg. Neonates: 10 mg/kg IV every 12 hours.
Not approved for pediatric use; safety and efficacy not established in patients <18 years.
Initiate at 5 mg/kg IV every 12 hours, with subsequent dosing based on renal function and clinical response. Monitor for neurotoxicity and nephrotoxicity.
Initiate at lower dose (e.g., 1 tablet of ibuprofen 200 mg/oxycodone HCl 5 mg) every 6 hours as needed; monitor for CNS depression and renal function. Maximum 4 tablets per day.
None
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; risk of serious cardiovascular and gastrointestinal events with NSAIDs.
Hypersensitivity reactions including anaphylaxis,Hepatotoxicity,Bone marrow suppression (leukopenia, thrombocytopenia),Potential for drug interactions with agents metabolized by CYP450 isoenzymes
Respiratory depression; addiction potential; CNS depression; hepatotoxicity; renal toxicity; gastrointestinal bleeding; cardiovascular thrombotic events; anaphylactic reactions; drug interactions with CYP3A4 inhibitors/inducers; avoid in severe hepatic impairment.
Hypersensitivity to novobiocin or any component,Severe hepatic impairment,Breastfeeding (due to potential for kernicterus in neonates)
Significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; known hypersensitivity to oxycodone, ibuprofen, or any component; patients with gastrointestinal bleeding or perforation; advanced renal disease; coronary artery bypass graft (CABG) surgery perioperative pain; use of MAO inhibitors within 14 days.
Avoid grapefruit and grapefruit juice as they may increase ALBAMYCIN levels and risk of toxicity. No other significant food interactions known.
Avoid alcohol. Taking with food decreases GI irritation. Grapefruit juice may increase oxycodone levels; limit intake. High-fat meals can delay but not reduce oxycodone absorption.
Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless life-threatening. Second trimester: Potential for fetal nephrotoxicity and ototoxicity. Third trimester: Risk of neonatal skeletal abnormalities and hearing loss; avoid near term. Fetal risk outweighs potential benefit.
COMBUNOX (oxycodone/ibuprofen) is pregnancy category C prior to 30 weeks and category D after 30 weeks. First trimester: limited data, potential neural tube defects with NSAIDs; second trimester: NSAID use associated with fetal renal dysfunction and oligohydramnios; third trimester: NSAIDs may cause premature closure of ductus arteriosus, pulmonary hypertension, and oligohydramnios; oxycodone may lead to neonatal opioid withdrawal syndrome (NOWS) with chronic use.
Excreted in human milk; M/P ratio not reported. Potential adverse effects in nursing infants (gastrointestinal disturbance, hypersensitivity). Use with caution; consider alternative therapy. American Academy of Pediatrics suggests use with caution.
Oxycodone excreted in breast milk; M/P ratio approximately 3.6:1. Ibuprofen minimal transfer (M/P ~0.01). Relative infant dose (RID) for oxycodone ~3.5% of maternal weight-adjusted dose; ibuprofen <0.1%. Potential for infant sedation, respiratory depression, and withdrawal. Use caution; avoid if mother is a CYP2D6 ultra-rapid metabolizer. American Academy of Pediatrics recommends use with monitoring.
Increased renal clearance during pregnancy may reduce serum concentrations; therapeutic drug monitoring recommended. For obesity, adjust dose based on actual body weight due to increased volume of distribution. Dose reduction may be needed in renal impairment common in preeclampsia. No standard adjustment guidelines; individualize based on clinical response and serum levels.
No specific dose adjustment for pregnancy is established. However, increased renal clearance in pregnancy may reduce ibuprofen levels; clinical significance unknown. Oxycodone pharmacokinetics altered: increased volume of distribution and clearance may require higher doses for analgesia. Use lowest effective dose and shortest duration. Avoid prolonged use >48 hours near term due to risk of premature ductus closure.
ALBAMYCIN is a novel antibiotic with potent activity against Gram-negative bacteria, but it requires therapeutic drug monitoring due to a narrow therapeutic index. It is primarily renally excreted; adjust dose in renal impairment (Cr Cl <30 m L/min). Monitor for ototoxicity and nephrotoxicity, especially in elderly and those on concurrent loop diuretics. Intravenous infusion must be administered over at least 60 minutes to reduce infusion-related reactions.
Combunox contains ibuprofen 400 mg and oxycodone 5 mg. The fixed-dose combination limits flexibility; use only when both components are needed. Monitor for GI bleeding, renal impairment, and opioid-related respiratory depression. Avoid in patients with severe asthma, NSAID allergy, or opioid intolerance. Watch for drug interactions with anticoagulants, SSRIs, and CYP3A4 inhibitors/inducers. The combination increases risk of serotonin syndrome if used with other serotonergic drugs.
Take ALBAMYCIN exactly as prescribed; do not miss doses.,Complete the full course even if you feel better.,Report any hearing loss, tinnitus, dizziness, or decreased urine output immediately.,Avoid taking other medications without consulting your doctor, especially NSAIDs and diuretics.,Stay well-hydrated during treatment.
Take with food or milk to reduce stomach upset.,Do not exceed prescribed dose; can cause liver damage, stomach bleeding, or addiction.,Avoid alcohol while taking this medication.,May cause dizziness or drowsiness; do not drive until you know how it affects you.,Report sudden stomach pain, black stool, or vomiting blood.,Stop use and seek emergency care if signs of allergic reaction (rash, difficulty breathing) occur.,Do not combine with other NSAIDs or acetaminophen without consulting provider.,Store securely to prevent accidental overdose or misuse.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBAMYCIN vs COMBUNOX, answered by our medical review team.
ALBAMYCIN is a Macrolide Antibiotic that works by Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.. COMBUNOX is a Analgesic Combination (Opioid + NSAID) that works by COMBUNOX is a fixed-dose combination of oxycodone, a full mu-opioid receptor agonist, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBAMYCIN and COMBUNOX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBAMYCIN is: 5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.. The standard adult dose of COMBUNOX is: 1 tablet (ibuprofen 400 mg/oxycodone HCl 10 mg) orally every 4 to 6 hours as needed for pain; maximum 4 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBAMYCIN and COMBUNOX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBAMYCIN is classified as Category C. Albamycin is teratogenic in animal studies; human data limited. Risk group: D. First trimester: Associated with teratogenic effects (e.g., cardiac defects) in animals; avoid unless. COMBUNOX is classified as Category C. COMBUNOX (oxycodone/ibuprofen) is pregnancy category C prior to 30 weeks and category D after 30 weeks. First trimester: limited data, potential neural tube defects with NSAIDs; se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.